Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 13 of 13 results for ivacaftor

  1. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

    Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.

    Technology appraisal guidance
    Published
    24 July 2024
    View recommendations

    Sections for TA988

  2. Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 [TSID10767]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over (TA1085)

    Evidence-based recommendations on vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) for treating cystic fibrosis in people 6 years and over with an F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

    Technology appraisal guidance
    Published
    30 July 2025
    View recommendations

    Sections for TA1085

  4. Topic prioritisation

    Find out what guidance is being considered for development

  5. Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued Reference number: GID-TA10277

    Technology appraisal guidance
    Discontinued

  7. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued Reference number: GID-TA10566

    Technology appraisal guidance
    Discontinued

  8. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

    NICE guideline
    Published
    25 October 2017
    View recommendations

    Sections for NG78

  9. Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

    Discontinued Reference number: GID-TA10390

    Technology appraisal guidance
    Discontinued

  10. Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg [TSID11894]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over [TSID11847]

    In development Reference number: GID-TA11372 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    This guidance has been updated and replaced by NICE technology appraisal guidance 988.

    Technology appraisal guidance
    Published
    27 July 2016

  13. Data collection agreement

    treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor (Kaftrio®) in combination with ivacaftor for...